Literature DB >> 34127728

Characteristics of left atrial remodeling in patients with atrial fibrillation and hypertrophic cardiomyopathy in comparison to patients without hypertrophy.

Sotirios Nedios1,2, Borislav Dinov3, Timm Seewöster3, Frank Lindemann3, Sergio Richter3, Arash Arya3, Nikolaos Dagres3, Daniela Husser3, Andreas Bollmann3, Gerhard Hindricks3, Andreas Müssigbrodt3,4.   

Abstract

Atrial fibrillation (AF) leads to remodeling characterized by changes in both size and shape of the left atrium (LA). Here we aimed to study the effect of hypertrophic cardiomyopathy (HCM) on the pattern of LA remodeling in AF-patients. HCM-patients (n = 23) undergoing AF ablation (2009-2012) were matched and compared with 125 Non-HCM patients from our prospective registry. Pre-procedural CT data were analyzed (EnSite Verismo, SJM, MN) to determine the maximal sagittal (anterior-posterior, AP), coronal (superior-inferior, SI and transversal, TV) dimensions and the sphericity index (LAS). Volume (LAV) was rendered after appendage (LAA) and pulmonary vein (PV) exclusion. A cutting plane, between PV ostia/LAA and parallel to the posterior wall, divided LAV into anterior- (LA-A) and posterior-LA (LA-P) parts. The ratio LA-A/LAV was defined as asymmetry index (ASI). HCM patients had a wider inter-ventricular septum and a smaller LV than Non-HCM patients. LA volume (LAV 166 ± 72 vs. 130 ± 36 ml, p = 0.03) and LA diameters were significantly larger in HCM patients. Anterior volume (LA-A: 112 ± 48 vs. 83 ± 26 ml, p < 0.001) differed significantly between groups, whereas the posterior volume LA-P (55 ± 28 vs. 47 ± 13 ml, p = 0.23) and LAS (75% vs. 78%, p = 0.089) was similar in both groups. As a result, ASI was significantly higher (67 ± 6 vs. 63 ± 6%, p = 0.01) in HCM than in Non-HCM patients. In conclusion, LA remodeling in patients with AF and HCM is characterized by asymmetric dilatation, driven by an anterior rather than a posterior dilatation. This can be characterized by three-dimensional imaging and could be used as surrogate of advanced atrial remodeling.

Entities:  

Year:  2021        PMID: 34127728     DOI: 10.1038/s41598-021-91892-y

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  27 in total

1.  Impact of asymmetrical dilatation of the left atrium on the long-term success after catheter ablation of atrial fibrillation.

Authors:  Sotirios Nedios; Emmanuel Koutalas; Jedrzej Kosiuk; Philipp Sommer; Arash Arya; Sergio Richter; Sascha Rolf; Daniela Husser; Gerhard Hindricks; Andreas Bollmann
Journal:  Int J Cardiol       Date:  2015-02-24       Impact factor: 4.164

2.  2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Authors:  Steve R Ommen; Seema Mital; Michael A Burke; Sharlene M Day; Anita Deswal; Perry Elliott; Lauren L Evanovich; Judy Hung; José A Joglar; Paul Kantor; Carey Kimmelstiel; Michelle Kittleson; Mark S Link; Martin S Maron; Matthew W Martinez; Christina Y Miyake; Hartzell V Schaff; Christopher Semsarian; Paul Sorajja
Journal:  J Am Coll Cardiol       Date:  2020-11-20       Impact factor: 24.094

3.  Characteristic changes of volume and three-dimensional structure of the left atrium in different forms of atrial fibrillation: predictive value after ablative treatment.

Authors:  Sotirios Nedios; Min Tang; Mattias Roser; Natalia Solowjowa; Jin-Hong Gerds-Li; Eckart Fleck; Charalampos Kriatselis
Journal:  J Interv Card Electrophysiol       Date:  2011-06-11       Impact factor: 1.900

4.  Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy.

Authors:  Carolyn Y Ho; Matthew E Mealiffe; Richard G Bach; Mondira Bhattacharya; Lubna Choudhury; Jay M Edelberg; Sheila M Hegde; Daniel Jacoby; Neal K Lakdawala; Steven J Lester; Yanfei Ma; Ali J Marian; Sherif F Nagueh; Anjali Owens; Florian Rader; Sara Saberi; Amy J Sehnert; Mark V Sherrid; Scott D Solomon; Andrew Wang; Omar Wever-Pinzon; Timothy C Wong; Stephen B Heitner
Journal:  J Am Coll Cardiol       Date:  2020-06-02       Impact factor: 24.094

Review 5.  Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management.

Authors:  Lohit Garg; Manasvi Gupta; Syed Rafay Ali Sabzwari; Sahil Agrawal; Manyoo Agarwal; Talha Nazir; Jeffrey Gordon; Babak Bozorgnia; Matthew W Martinez
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

6.  Left atrial sphericity: a new method to assess atrial remodeling. Impact on the outcome of atrial fibrillation ablation.

Authors:  Felipe Bisbal; Esther Guiu; Naiara Calvo; David Marin; Antonio Berruezo; Elena Arbelo; José Ortiz-Pérez; Teresa María de Caralt; José María Tolosana; Roger Borràs; Marta Sitges; Josep Brugada; Lluís Mont
Journal:  J Cardiovasc Electrophysiol       Date:  2013-03-14

7.  Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM Cardiac Magnetic Resonance Substudy Analysis.

Authors:  Sara Saberi; Nuno Cardim; Mohamad Yamani; Jeanette Schulz-Menger; Wanying Li; Victoria Florea; Amy J Sehnert; Raymond Y Kwong; Michael Jerosch-Herold; Ahmad Masri; Anjali Owens; Neal K Lakdawala; Christopher M Kramer; Mark Sherrid; Tim Seidler; Andrew Wang; Farbod Sedaghat-Hamedani; Benjamin Meder; Ofer Havakuk; Daniel Jacoby
Journal:  Circulation       Date:  2020-11-15       Impact factor: 29.690

8.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.

Authors:  Gerhard Hindricks; Tatjana Potpara; Nikolaos Dagres; Elena Arbelo; Jeroen J Bax; Carina Blomström-Lundqvist; Giuseppe Boriani; Manuel Castella; Gheorghe-Andrei Dan; Polychronis E Dilaveris; Laurent Fauchier; Gerasimos Filippatos; Jonathan M Kalman; Mark La Meir; Deirdre A Lane; Jean-Pierre Lebeau; Maddalena Lettino; Gregory Y H Lip; Fausto J Pinto; G Neil Thomas; Marco Valgimigli; Isabelle C Van Gelder; Bart P Van Putte; Caroline L Watkins
Journal:  Eur Heart J       Date:  2021-02-01       Impact factor: 29.983

9.  Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe).

Authors:  Carolyn Y Ho; Sharlene M Day; Euan A Ashley; Michelle Michels; Alexandre C Pereira; Daniel Jacoby; Allison L Cirino; Jonathan C Fox; Neal K Lakdawala; James S Ware; Colleen A Caleshu; Adam S Helms; Steven D Colan; Francesca Girolami; Franco Cecchi; Christine E Seidman; Gautam Sajeev; James Signorovitch; Eric M Green; Iacopo Olivotto
Journal:  Circulation       Date:  2018-08-23       Impact factor: 29.690

10.  Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Iacopo Olivotto; Artur Oreziak; Roberto Barriales-Villa; Theodore P Abraham; Ahmad Masri; Pablo Garcia-Pavia; Sara Saberi; Neal K Lakdawala; Matthew T Wheeler; Anjali Owens; Milos Kubanek; Wojciech Wojakowski; Morten K Jensen; Juan Gimeno-Blanes; Kia Afshar; Jonathan Myers; Sheila M Hegde; Scott D Solomon; Amy J Sehnert; David Zhang; Wanying Li; Mondira Bhattacharya; Jay M Edelberg; Cynthia Burstein Waldman; Steven J Lester; Andrew Wang; Carolyn Y Ho; Daniel Jacoby
Journal:  Lancet       Date:  2020-08-29       Impact factor: 79.321

View more
  1 in total

1.  Transaortic Shallow Septal Myectomy and Cutting of Secondary Fibrotic Mitral Valve Chordae-A 5-Year Single-Center Experience in the Treatment of Hypertrophic Obstructive Cardiomyopathy.

Authors:  Lucian Florin Dorobantu; Toma Andrei Iosifescu; Razvan Ticulescu; Maria Greavu; Maria Alexandrescu; Andrei Dermengiu; Miruna Mihaela Micheu; Monica Trofin
Journal:  J Clin Med       Date:  2022-05-30       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.